Organon OGN Latin America, Middle East, Russia, and Africa — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's latin america, middle east, russia, and africa — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's latin america, middle east, russia, and africa — revenue?
- Organon (OGN) reported latin america, middle east, russia, and africa — revenue of $247M in Q1 2026.
- How has Organon's latin america, middle east, russia, and africa — revenue changed year-over-year?
- Organon's latin america, middle east, russia, and africa — revenue increased by 2.9% year-over-year, from $240M to $247M.
- What is the long-term trend for Organon's latin america, middle east, russia, and africa — revenue?
- Over 4 years (2021 to 2025), Organon's latin america, middle east, russia, and africa — revenue has grown at a 6.3% compound annual growth rate (CAGR), from $841M to $1.07B.
- What does latin america, middle east, russia, and africa — revenue mean?
- This metric represents the total net sales generated from pharmaceutical products within the Latin America, Middle East, Russia, and Africa geographic region. It reflects the company's market penetration and commercial performance in these emerging and diverse markets across its women's health, biosimilars, and established medicines portfolios. Tracking this revenue stream provides insight into the company's geographic diversification and its ability to capture growth in non-core developed markets.